Surrozen Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Surrozen Inc.
- Former names
- Consonance-HFW Acquisition Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SRZN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001824893
- EIN
- 30-1374889
Board of directors
-
Anna Berkenblit · DirectorSince 2023
-
Christopher Y. Chai · DirectorSince 2023
-
Craig C. Parker · Director · Chief Executive OfficerSince 2023
-
David J. Woodhouse · DirectorSince 2023
-
Eric Bjerkholt · DirectorSince 2023
-
Mace Rothenberg · DirectorSince 2023
-
Mary Haak-Frendscho · DirectorSince 2023
-
Shao-Lee Lin · DirectorSince 2023
-
Tim Kutzkey · DirectorSince 2025
Chief executives
Craig C. Parker
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.4%
-
100.0%
Board connections
3 of this board's directors also sit on 5 other boards.
- via Eric Bjerkholt
- via Eric Bjerkholt
- via Shao-Lee Lin
- via Eric Bjerkholt
- via Mace Rothenberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $16,849,701
- 56 purchases by 6 insiders
- Sold, last 12 months
- $7,231,021
- 7 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 22, 2026 | TCG Crossover GP II, LLC 10% owner | Open-market sale | −162,500 | $21.25 | $3,453,125 |
| Jul 22, 2026 | TCG Crossover GP II, LLC 10% owner | Open-market sale | −162,500 | $21.25 | $3,453,125 |
| Jun 15, 2026 | Maleki Andrew Pedrum Officer (Chief Financial Officer) | Grant or award | +607 | $19.01 | $11,539 |
| Jun 15, 2026 | Li Yang Officer (Exec. Vice President, Research) | Grant or award | +1,666 | $8.11 | $13,511 |
| Jun 15, 2026 | Williams Charles O Officer (Chief Operating Officer) | Grant or award | +1,666 | $8.11 | $13,511 |
| Jun 15, 2026 | Craig C. Parker Director, Officer (Chief Executive Officer) | Grant or award | +1,622 | $8.11 | $13,154 |
| May 4, 2026 | Li Yang Officer (Exec. Vice President, Research) | Open-market sale | −1,584 | $33.33 | $52,795 |
| May 4, 2026 | Williams Charles O Officer (Chief Operating Officer) | Open-market sale | −2,036 | $33.33 | $67,860 |
| May 4, 2026 | Craig C. Parker Director, Officer (Chief Executive Officer) | Open-market sale | −4,524 | $33.33 | $150,785 |
| May 1, 2026 | Li Yang Officer (Exec. Vice President, Research) | Option exercise | +4,375 | — | — |
| May 1, 2026 | Williams Charles O Officer (Chief Operating Officer) | Option exercise | +5,625 | — | — |
| May 1, 2026 | Craig C. Parker Director, Officer (Chief Executive Officer) | Option exercise | +12,500 | — | — |
| Mar 31, 2026 | Li Yang Officer (Exec. Vice President, Research) | Gift | −1,666 | — | — |
| Mar 24, 2026 | TCG Crossover Fund II, L.P. 10% owner | Open-market purchase | +53,329 | $24.69 | $1,316,693 |
| Mar 24, 2026 | TCG Crossover Fund II, L.P. 10% owner | Open-market purchase | +53,329 | $24.69 | $1,316,693 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.